PREVAIL VIIIa: Piilevän tuberkuloosiinfektion seulontamenetelmien arviointi ihmisillä, joilla on retrovirusinfektio Liberiassa
Background:
Tuberculosis (TB) is a health threat for people living with human immunodeficiency virus (HIV). People living with HIV are more likely than others to develop active TB. Also, TB makes HIV progress faster. TB is a leading cause of death among people in the West African country of Liberia. Researchers want to find an effective testing method for latent tuberculosis infection (LTBI) to help people living with HIV in Liberia.
Objective:
To compare the interferon-gamma release assay (IGRA) and tuberculin skin test (TST) as LTBI screening tests in people living with HIV in Liberia.
Eligibility:
People ages 18 and older who take part in NIH study #19-I-N014 and are scheduled to have or have had IGRA at a Month 12 HONOR study visit.
Design:
Participants will be screened with a medical history and physical exam. Their medical records and HONOR study records will be reviewed.
Participants will have TST. Purified protein derivative will be placed in the skin of their forearm. They will be observed for adverse reactions for 15 minutes. Between 48 and 72 hours after placement, they will have a second study visit to have the TST read. If they miss this time frame, they can return up to 7 days after placement. If they have a positive test result, they will have a chest x-ray. They will have a third study visit to review the results of the chest x-ray. They will be referred for clinical care if needed. They will take a pregnancy test if needed.
Participation will last from 2 days to 6 weeks.
...
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
Study Description:
This is a prospective study to compare the interferon-gamma release assay (IGRA) and tuberculin skin test (TST) as latent tuberculosis infection (LTBI) screening tests in people living with HIV in Liberia. Participants will be co-enrolled on the ongoing HONOR (A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living with Retroviral Infection in Liberia) study. A TST will be administered to eligible participants who are being screened by IGRA on HONOR. Since there is no gold standard for diagnosing LTBI, the results of each method will be compared to evaluate whether there is no difference in the probability of testing positive, assess the operational functionality in the clinic and lab, and determine whether one test can be used with greater sensitivity assuming comparable specificity.
In an extension phase, participants who had a positive TST and/or IGRA result will be offered an opportunity to return for an optional assessment by follow-up chest x-ray, non-contrast chest computed tomography (CT) scanning, sputum collection, and phlebotomy. This will involve an additional visit (Visit 4), to occur after completion of the primary phase (Visit 3). The visit may occur in conjunction with (ie, the same day as or within 4 weeks of) a main HONOR study visit, and results of blood tests collected under the main HONOR study will be reviewed. For participants who have already completed the main HONOR study or do not have an upcoming HONOR visit scheduled, a new visit (ie, HONOR TB Visit 4) will be scheduled for this HONOR TB extension study, and a blood draw will also be performed.
Objectives:
Primary Objective: Assess the sensitivity of the IGRA and TST as LTBI screening tools in people living with HIV in Liberia.
Secondary Objective: Assess the operational functionality of the IGRA and TST in Liberia.
Exploratory Objective: Investigate testing approaches, including follow-up chest x-ray imaging, high-resolution chest CT imaging, and performance on sputum of the Mycobacterium tuberculosis (MTB) complex/rifampin (RIF) nucleic acid amplification test (NAAT), to improve diagnosis of stage-specific TB infection by examining how classification of TB status is associated with biomarker levels (only for participants with a positive TST and/or IGRA).
Endpoints:
Primary Endpoint: Frequency of positive results using the IGRA and TST.
Secondary Endpoint: Proportion of each test type successfully completed and the result determined.
Exploratory Endpoint: Repeat chest x-ray assessment, non-contrast chest CT assessment, sputum analysis by MTB/RIF NAAT assay, and analysis of serum by a CRISPR-Mtb-cfDNA assay.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Kakata, Liberia
- C.H. Rennie Hospital
-
Monrovia, Liberia
- Redemption Hospital
-
Monrovia, Liberia
- Duport Road Clinic
-
Monrovia, Liberia
- JFK Medical Center
-
-
-
-
Maryland
-
Bethesda, Maryland, Yhdysvallat, 20892
- National Institutes of Health Cinical Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Adult participants must be enrolled in the main HONOR study of people living with HIV in Liberia who participated in the HONOR TB study at their Month 12 visit and tested positive on IGRA and/or TST.
Kuvaus
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Be a participant on the PREVAIL VIII/HONOR study.
- Be at least 18 years of age.
- Be scheduled to undergo or have undergone IGRA at a Month 12 HONOR study visit.
- Ability to return to the clinic 48 to 72 hours after TST placement for reading.
- Ability to provide informed consent.
In order to be eligible to participate in the extension phase of the study, an individual must meet all of the following criteria:
- Participated in the PREVAIL VIIIa HONOR TB study.
- Have had a positive TB test result on the TST and/or IGRA performed as part of the PREVAIL VIII HONOR or PREVAIL VIIIa HONOR TB study(ies).
- Ability to provide informed consent.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this
study:
- Received BCG vaccine <=10 years prior.
- Known hypersensitivity or allergy to any component of the PPD product.
- Previous severe reaction (e.g., necrosis, blistering, ulcerations, or anaphylactic shock) to a TST.
- Documented active TB or a clear history of treatment for latent infection or active disease.
- Extensive burns or eczema or other skin conditions on the forearms that could affect placement and reading of the TST.
- Pregnant or lactating women.
- Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study.
An individual who meets any of the following criteria will be excluded from participation in the extension phase of this study:
- Pregnant women.
- Contraindication to CT scanning.
- Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study.
Exclusion of Special Populations (Children, Adults Who Lack Capacity to Consent, and Pregnant Women)
-We are able to obtain knowledge about TST performance in Liberia without exposing children, adults who lack capacity to consent, and pregnant women to the potential risk of reactions to the TST or exposure to radiation for research purposes.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
HONOR TB participants with positive IGRA and/or TST during initial phase
Adult participants who who tested positive on IGRA and or TST during initial phase and meet the study-specific eligibility criteria. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Frequency of positive results using the IGRA and TST.
Aikaikkuna: 48-72 hours after TST placement
|
Assess the sensitivity of the IGRA and TST as LTBI screening tools in people living with HIV in Liberia. |
48-72 hours after TST placement
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of each test type successfully completed and the result determined.
Aikaikkuna: 48-72 hours after TST placement
|
Assess the operational functionality of the IGRA and TST. |
48-72 hours after TST placement
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Stephen A Migueles, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 10000231
- 000231-I
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Individual participant data that underline the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD-jaon aikakehys
Beginning 9 months and ending 36 months following article publication.
IPD-jaon käyttöoikeuskriteerit
Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Utilized for individual participant data meta-analysis. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our database but without investigator support.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .